New form of Tysabri makes access easier

The disease-modifying therapy natalizumab has been authorised for use as a subcutaneous (SC) injection to treat people with relapsing-remitting multiple sclerosis (RRMS).

Natalizumab, also known as Tysabri, has previously been administered intravenously. However, last week, Biogen UK announced that the Medicines and Healthcare products Regulatory Agency (MHRA) have authorised the SC version, offering two different administration methods - and potentially expanding access to the treatment.

This version of natalizumab means the drug can now be administered more quickly and conveniently outside of traditional healthcare settings. Whilst still requiring medical oversight and monitoring, the injectible version could allow for more community, place-based care and reduced demand on infusion centres - particularly helpful as we continue to manage the coronavirus pandemic.